Kodiak Sciences Inc

As of June 30, 2026, Kodiak Sciences, Inc. carries a market capitalization of 46.91B, placing it among publicly traded companies globally. Its enterprise value stands at 45.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kodiak Sciences, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Kodiak Sciences, Inc. has 62.83M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Kodiak Sciences, Inc. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Kodiak Sciences, Inc. posted a negative return on equity (ROE) of -368.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -94.25, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 120.25, a quick read on workforce productivity versus industry peers.

As of the close on October 14, 2026, Kodiak Sciences, Inc.'s stock has gained approximately 2841.18% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Kodiak Sciences, Inc. generated - - in revenue and converted that into -4.23B in net income, yielding earnings per share of -72.97. EBITDA reached -3.86B, while operating income came in at -4.31B.

As of June 30, 2026, Kodiak Sciences, Inc. holds 2.20B in cash and equivalents against 921.73M in total debt, resulting in a net debt position of -2.20B. Total book value stands at 1.07B, with working capital of 1.37B providing operational flexibility.

Kodiak Sciences, Inc. produced -2.77B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -24.41M in capital expenditures, free cash flow totaled -2.79B - equivalent to -48.21 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.77, meaning Kodiak Sciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Kodiak Sciences, Inc. has an Altman Z-Score of -3.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.